The Mounjaro price increase and what it means for access in the UK

Step 1: understand exactly what changed on 1 September 2025

Eli Lilly raised Mounjaro's UK list price on 1 September 2025. The scale of the increase was uneven across doses, the biggest impact landed at the top of the titration schedule, where the list price for the highest-dose pen moved from roughly £122 to roughly £330. Lower doses rose by smaller amounts, but the direction was the same across the range. As widely reported in August 2025, Lilly cited the medicine's clinical value and demand; the company did not commit to a price cap for private supply.

Private providers, who set their own margins and overheads, responded at different rates. As of mid-2026, typical private monthly costs sit broadly between £149 and £375 depending on dose, clinic and what is actually included. Patients who started treatment at 2.5mg and had planned a full titration suddenly faced a bill at maintenance dose that was two to three times what they had budgeted, often after already investing months in the process. You can read a more detailed breakdown of the individual dose changes on our Mounjaro price increase page.

Step 2: work out what headline prices do and don't include

One reason the inequality problem runs deeper than the list price alone: advertised monthly costs vary substantially in what they cover. A number at the top of a search result does not always include the clinical consultation, the prescription charge, or any aftercare if side effects arise mid-month. Some providers separate these out as individual line items. Others charge for video reviews, for dose-increase assessments, or for the packaging and delivery separately.

This matters for inequality because the true cost of private treatment, carefully totted up, often exceeds the headline figure, and that gap falls hardest on patients who are price-checking precisely because money is tight. A £149 headline that becomes £200 once you add the prescription fee and delivery is a different proposition from the start. Our Mounjaro price comparison chart covers this in practical detail, comparing what different providers typically include.

It is also worth noting that the cost of treatment is not only the pen. Missed doses through supply shortages, needing to restart titration, or stopping treatment early because a dose increase became unaffordable each carry their own clinical and financial cost. The full cost increase picture goes beyond any single pen's price.

Step 3: understand nume's position honestly

A named prescriber (a real clinician, not an automated filter) reads every consultation at nume. That review happens the same day you submit it, and if it's before 12pm on a working day and treatment is clinically suitable, your prescription is dispatched the same day. What comes through the letterbox is a DPD-tracked delivery in a plain, unbranded box: your pen, your Patient Information Leaflet, nothing identifying on the outside.

That service has a price, and we will say plainly that it is not the lowest one available. We are not trying to win a price comparison. What the single amount we charge covers: the consultation, the prescription, the medicine itself, delivery, and priority aftercare seven days a week. No subscription. No auto-renewal. A prescriber reviews each repeat before anything is sent. For the 5mg dose specifically, you can see what that part of the range looks like on our 5mg price increase page.

The inequality this page is really about is not something a private pharmacy can solve unilaterally, Eli Lilly sets the list price, and the NHS rollout for tirzepatide remains phased and restricted. What we can do is be precise about what you get, so you're comparing like with like rather than a headline against a reality. You can also read about providers that did not raise prices and what that typically means in practice.

Step 4: consider what the NHS route actually offers, and whether it applies to you

Tirzepatide is available on the NHS, but the access criteria are strict and deliberately phased. As of June 2025, NHS eligibility required a BMI of 40 or above plus four or more of five specified weight-related conditions. A second cohort (BMI 35–39.9 with four or more conditions) became eligible from June 2026. These thresholds mean that many people who would benefit clinically, and who could not sustain private costs after the September 2025 price rise, currently sit outside NHS criteria entirely. NICE's appraisal of tirzepatide, published as TA1026, sets out the full NHS eligibility framework and phasing schedule.

GP practices may now prescribe under the 2026/27 QOF contract, but participation varies by practice. The honest picture: NHS access is expanding, but slowly, and it does not reach the majority of people who have been using private routes. If you want to understand whether you currently meet NHS criteria, your GP is the right starting point. If NHS access isn't available to you and you want to explore the private route with full clarity on what is included, our free consultation is the place to start, no commitment, no upfront cost, just a clinical review of your situation. You can also read more about weight loss treatment options more broadly, or explore the 2.5mg price increase if you're early in titration and trying to plan ahead.